+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Aerie Pharmaceuticals - logo

Aerie Pharmaceuticals is a company that focuses on the development and commercialization of therapies for the treatment of glaucoma and other eye diseases. The National Eye Institute expects the number of people in the United States suffering from glaucoma to reach 4.3 million by 2030. Aerie was founded in 2005 and went in public in 2013, raising $67 million in its IPO. Its product candidates include Rhopressa and Roclatan. The company is headquartered in Irvine, California.

From
Diabetic Retinopathy - Pipeline Review, H2 2020 - Product Thumbnail Image

Diabetic Retinopathy - Pipeline Review, H2 2020

  • Drug Pipelines
  • November 2020
  • 358 pages
From
Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H2 2020 - Product Thumbnail Image

Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H2 2020

  • Drug Pipelines
  • September 2020
  • 57 pages
From
From
From
From
From
From
Global Retinal Drugs Market 2021-2025 - Product Thumbnail Image

Global Retinal Drugs Market 2021-2025

  • Report
  • March 2021
  • 120 pages
From
From
From
From
From
From
Loading Indicator
adroll